The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous systemincluding psychiatric drugsare assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine’s (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Achetez cet ebook et obtenez-en 1 de plus GRATUITEMENT !
Langue Anglais ● Format PDF ● Pages 88 ● ISBN 9780309148849 ● Éditeur Bruce Altevogt & Miriam Davis ● Maison d’édition National Academies Press ● Publié 2010 ● Téléchargeable 3 fois ● Devise EUR ● ID 7141514 ● Protection contre la copie Adobe DRM
Nécessite un lecteur de livre électronique compatible DRM